Dr. Michael Wyand on The Innovation Blueprint Podcast

Oxeia CEO Dr. Michael Wyand recently sat down with Phil Therien on The Innovation Blueprint podcast for a candid conversation about concussion, OXE103, and what it actually takes to build a treatment for an injury the medical system has overlooked.

Here's what he had to say about why concussion was ignored for so long:

"There have been no concussion drugs that have ever had data submitted to the FDA. Now we know it's severe — it leads to dementia, it leads to chronic traumatic encephalopathy. But the brain, we can't see it. It's not like somebody twists their knee and they're limping. So it was ignored."

He also broke down what actually happens inside the brain during a concussion — and why OXE103, a naturally occurring ghrelin molecule licensed from Daiichi Sankyo, matches the biology of the injury:

"Shock waves cause your brain to depolarize. All the brain cells in your head just get active and fire off their energy. It's like draining the battery. The battery of the brain just drains down. And that happens instantaneously."

And on the challenge of building a first-in-class treatment without the venture capital playbook behind it:

"If I had AI in the name of our program, God, I'd have money pouring over me."

The full conversation covers the science behind OXE103, Oxeia's 80% responder rate in Phase 2a vs. 33% standard of care, the path to Phase 2b, and why the crowd may be the ones to fund what traditional capital won't.

Join the mission to bring the first FDA-approved treatment for persistent concussion symptoms to market. Visit our campaign page on StartEngine .

This Reg CF offering is made available through StartEngine Primary LLC, member FINRA/SIPC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.